



## Search

 [Advanced search](#)

## Corporate Responsibility

[Bioethics Policy](#)  
[Code of Conduct](#)

## Quick links - Products

[Accolate™ \(zafirlukast\)](#)  
[Arimidex™ \(anastrozole\)](#)  
[Atacand™ \(candesartan cilexetil\)](#)  
[Casodex™ \(bicalutamide\)](#)  
[Crestor™ \(rosuvastatin\)](#)  
[Diprivan™ \(propofol\)](#)  
[Entocort™ \(budesonide\)](#)  
[Exanta™ \(ximelagatran\)](#)  
[Faslodex™ \(fulvestrant\)](#)  
[Iressa™ \(gefitinib\)](#)  
[Losec™ \(omeprazole\)](#)  
[Merrem™ \(meropenem\)](#)  
[Naropin™ \(ropivacaine\)](#)  
[Nexium™ \(esomeprazole\)](#)  
[Oxis™ \(formoterol\)](#)  
[Products in Development](#)  
[Pulmicort™ \(budesonide\)](#)  
[Rhinocort™ \(budesonide\)](#)  
[Seroquel™ \(quetiapine\)](#)  
[Symbicort™ \(budesonide/formoterol\)](#)  
[Zoladex™ \(goserelin acetate\)](#)  
[Zomig™ \(zolmitriptan\)](#)

## Page tools

[Bookmark this site](#)  
[Bookmark this page](#)  
[Printer friendly](#)  
[Print this chapter](#)

## Seroquel™ (quetiapine) Clinical Trial report summaries

Seroquel™ (quetiapine) was first approved in 1997 for schizophrenia. Since the formation of AstraZeneca, Seroquel™ (quetiapine) has received approval for bipolar mania.

Please consult the prescribing information for the country concerned for guidance on the approved use of Seroquel™ (quetiapine).

| Study Number                | Completed Clinical Trial Report Summaries  |
|-----------------------------|--|
| <a href="#">5077IL/0039</a> | A Multicenter, Double-blind Comparison of Efficacy and Safety of Seroquel™ (Quetiapine Fumarate), Haloperidol, and Placebo in the Treatment of Elderly Subjects Residing in Nursing Homes or Assisted Care Facilities and Presenting with Alzheimer's Dementia and Psychoses or Other Selected Psychoses |
| <a href="#">5077IL/0050</a> | A Multicentre, Double-blind, Randomised Trial to Compare the Effects of Quetiapine and Haloperidol Treatment Strategies on Treatment Outcomes (5077IL/0050[ESTO])  |
| <a href="#">5077IL/0099</a> | A Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the Safety and Efficacy of Seroquel™ (Quetiapine Fumarate) as Add-on Therapy with Lithium or Divalproex in the Treatment of Acute Mania   |
| <a href="#">5077IL/0100</a> | An International, Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Seroquel™ (Quetiapine Fumarate) as Add-on Therapy with Lithium or Divalproex in the Treatment of Acute Mania   |
| <a href="#">5077IL/0104</a> | An International, Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Seroquel™ (Quetiapine Fumarate) and Haloperidol as Monotherapy in the Treatment of Acute Mania   |
| <a href="#">5077IL/0105</a> | An International, Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Seroquel™ (Quetiapine Fumarate) and Lithium as Monotherapy in the Treatment of Acute Mania   |
| <a href="#">5077US/0043</a> | A Multicenter, Double-blind, Randomized Comparison of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™) and Risperidone (RISPERDAL™) in the Treatment of Patients with Schizophrenia  |
| <a href="#">5077US/0046</a> | A Multicenter, Double-blind, Randomized Comparison of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™) and Placebo in the Treatment of Agitation Associated with Dementia  |
| <a href="#">5077US/0049</a> | A Multicenter, Double-blind, Randomized, Placebo-controlled, Double-dummy Trial of the Use of Quetiapine Fumarate (Seroquel™) in the Treatment of Patients with Bipolar Depression   |
| <a href="#">D1447C00135</a> | A Confirmatory Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Use of Quetiapine Fumarate (Seroquel™) in the Treatment of Patients with Bipolar Depression.   |
| <a href="#">D1444C00132</a> | A 6-week, International, Multicenter, Double-blind, Double-dummy, Randomized Comparison of the Efficacy and Safety of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL™) and Placebo in the Treatment of Acutely Ill Patients with Schizophrenia.   |

## Home

## Clinical trials

- » [Accolate™ \(zafirlukast\)](#)
- » [Arimidex™ \(anastrozole\)](#)
- » [Atacand™ \(candesartan cilexetil\)](#)
- » [Casodex™ \(bicalutamide\)](#)
- » [Crestor™ \(rosuvastatin\)](#)
- » [Diprivan™ \(propofol\)](#)
- » [Entocort™ \(budesonide\)](#)
- » [Exanta™ \(ximelagatran\)](#)
- » [Faslodex™ \(fulvestrant\)](#)
- » [Iressa™ \(gefitinib\)](#)
- » [Losec™ \(omeprazole\)](#)
- » [Merrem™ \(meropenem\)](#)
- » [Naropin™ \(ropivacaine\)](#)
- » [Nexium™ \(esomeprazole\)](#)
- » [Oxis™ \(formoterol\)](#)
- » [Plendil™ \(felodipine\)](#)
- » [Products in Development](#)
- » [Pulmicort™ \(budesonide\)](#)
- » [Rhinocort™ \(budesonide\)](#)
- » [Seloken ZOK/Toprol-XL™ \(metoprolol CR/XL\)](#)
- » [Seroquel™ \(quetiapine\)](#)
- » [- Ongoing Studies](#)
- » [Symbicort™ \(budesonide/formoterol\)](#)
- » [Zoladex™ \(goserelin acetate\)](#)
- » [Zomig™ \(zolmitriptan\)](#)

## Glossary

## Contact us

## Sitemap

|                        |   |
|------------------------|---|
| D1444C00133            | A 6-week, Multicenter, Double-blind, Double-dummy, Randomized Comparison of the Efficacy and Safety of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL™) and Placebo in the Treatment of Acutely Ill Patients with Schizophrenia.             |
| 5077IL/0041            | A Multicenter, Double-blind, Randomized Comparison of the Efficacy and Safety of Sustained-release Formulation Quetiapine Fumarate (SEROQUEL™) and Placebo in the Treatment of Patients With Schizophrenia.   |
| D1441C00023            | A Canadian, Multicentre, Double-Blind, Randomized, Parallel-Group Study of the Safety, Tolerability, and Efficacy of Treatment with Higher Doses of Quetiapine Fumarate (Seroquel™) greater than 800 mg/day in Schizophrenic or Schizoaffective Subjects. |
| D1441L00002            | Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52 Week Comparison.  |
| D1446L00002            | A Multicenter, Double-blind, Randomized Comparison of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) and Placebo in the Treatment of Agitation Associated with Dementia   |
| 5077IL/125             | Trial results awaiting further analysis and interpretation. Anticipated posting date is January 2008.   |
| D1444C00004 (PRINCESS) | Trial results awaiting further analysis and interpretation. Anticipated posting date is January 2008.   |
| D1444C00146            | Trial results awaiting further analysis and interpretation. Anticipated posting date is January 2008.   |
| D1444C00147            | A 12-week International, Multicenter, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching any Antipsychotic Treatment to Sustained-release quetiapine Fumarate (SEROQUEL®) in Patients with Schizophrenia                          |
| D1441C00149            | Trial results awaiting further analysis and interpretation. Anticipated posting date is January 2009.   |

